Our in-depth knowledge of drug discovery spans multiple target classes. We can carry out in vitro microbial testing to establish the MIC (minimum inhibitory concentrations) of test compounds versus ESKAPE pathogens. We also validate cell-based and non cell-based assays for primary pharmacology screening and mechanism of action.
Other areas of expertise include ion channel safety (hERG, Nav, Cav) and CiPA compliant cardiac myocyte profiling. Our team provides support for compound design and computational chemistry (via Cresset) as well as extensive project management services.
This integration of pharmacology, ADMET, medicinal chemistry and computational chemistry is key to SAR development and optimising leads.